×
About 255 results

ALLMedicine™ Pediatric Neuroblastoma Center

Research & Reviews  74 results

Current Status and Future Perspective on Molecular Imaging and Treatment of Neuroblastoma.
https://doi.org/10.1053/j.semnuclmed.2022.12.004
Seminars in Nuclear Medicine; Feng L, Li S et. al.

Jan 23rd, 2023 - Neuroblastoma is the most common extracranial solid tumor in children and arises from anywhere along the sympathetic nervous system. It is a highly heterogeneous disease with a wide range of prognosis, from spontaneous regression or maturing to hi...

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
https://clinicaltrials.gov/ct2/show/NCT04753658

Nov 21st, 2022 - The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.

Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
https://clinicaltrials.gov/ct2/show/NCT02924324

Nov 8th, 2022 - The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The...

Imaging of pediatric neuroblastoma: A COG Diagnostic Imaging Committee/SPR Oncology Com...
https://doi.org/10.1002/pbc.29974
Pediatric Blood & Cancer; Lai HA, Sharp SE et. al.

Oct 3rd, 2022 - Neuroblastoma is the most common extracranial solid neoplasm in children. This manuscript provides consensus-based imaging recommendations for pediatric neuroblastoma patients at diagnosis and during follow-up.

Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497977
Current Oncology (Toronto, Ont.); Chilamakuri R, Agarwal S

Sep 23rd, 2022 - The Raf-MEK-ERK signaling network has been the subject of intense research due to its role in the development of human cancers, including pediatric neuroblastoma (NB). MEK and ERK are the central components of this signaling pathway and are attrac...

see more →

Clinicaltrials.gov  8 results

Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
https://clinicaltrials.gov/ct2/show/NCT04753658

Nov 21st, 2022 - The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.

Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients
https://clinicaltrials.gov/ct2/show/NCT02924324

Nov 8th, 2022 - The purpose of this study is to identify whether or not the addition of a numbing medicine that is injected directly into the site of the bone marrow procedure can reduce pain and the use of opioid pain medication after bone marrow procedures. The...

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Pediatric Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT05027386

Aug 31st, 2021 - The enrolled patients diagnosed with recurrent or refractory pediatric neuroblastoma received apatinib combined with IT regimen chemotherapy, the treatment including combination therapy phase and monotherapy maintenance phase.

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
https://clinicaltrials.gov/ct2/show/NCT02332889

May 4th, 2018 - One of the challenges of the practical application of immunotherapy for brain tumors is the lack of expression of tumor antigens as well as the down-regulation of Major Histocompatibility Complex (MHC Class I and II ) molecules, which are needed f...

Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma
https://clinicaltrials.gov/ct2/show/NCT02615106

Jun 14th, 2016 - Clinical data proved that Endostar was a wild spectrum and safe antiangiogenesis factor which could suppress almost 65 kinds of tumor mass in animal models and affect about 12 percent human genome. So investigators design Radiotherapy plus Endosta...

see more →

News  20 results

FDA Panel Votes Against Omburtamab for Rare Pediatric Cancer
https://www.medscape.com/viewarticle/983268

Oct 31st, 2022 - Y-mAbs Therapeutics has suffered a setback in its efforts to win US approval for I-omburtamab to treat a rare pediatric cancer. On October 28, a Food and Drug Administration (FDA) advisory panel found a lack of evidence to support the drug's appro...

Hispanic Ethnicity Associated With Poorer OS in Pediatric Neuroblastoma
https://www.onclive.com/view/hispanic-ethnicity-associated-with-poorer-os-in-pediatric-neuroblastoma

May 26th, 2022 - Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival (OS) rates compared with other children, according to an analysis of data from Children’s Oncology Group...

Activating the Immune System Could be Key to Treating Pediatric Neuroblastoma
https://www.onclive.com/view/activating-the-immune-system-could-be-key-to-treating-pediatric-neuroblastoma

Mar 10th, 2022 - Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma. Wayne Furman, MD, hopes that the humanized anti-disialoganglioside (anti-GD2) monoclonal antibody hu14.18K322A provides a breakthrough for children wi...

Rare Cancers Report: Pediatric Neuroblastoma
https://www.onclive.com/view/rare-cancers-report-pediatric-neuroblastoma

Feb 3rd, 2022 - Welcome to OncLiveOn Air®! I’m your host today, Jessica Hergert. OncLiveOn Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and p...

Yale Cancer Center Researchers Show Receptor Structure Reveals New Targets for Cancer Treatment
https://www.onclive.com/view/yale-cancer-center-researchers-show-receptor-structure-reveals-new-targets-for-cancer-treatment

Dec 10th, 2021 - A molecule known as anaplastic lymphoma kinase (ALK) is a driver of several cancers, including pediatric neuroblastoma, B-cell lymphomas, and myofibroblast tumors. But for years much about this molecule — its role in the body, which molecules inte...

see more →